DB
SNOA icon

Danske Bank’s Sonoma Pharmaceuticals SNOA Stock Holding History

Danske Bank’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 1148
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1146
2025
Q4 		$4 Hold
1
– – ﹤0.01% 1515
2025
Q3 		$4 Hold
1
– – ﹤0.01% 1447
2025
Q2 		$3 Hold
1
– – ﹤0.01% 1491
2025
Q1 		$2 Hold
1
– – ﹤0.01% 1347
2024
Q4 		$3 Hold
1
– – ﹤0.01% 1370
2024
Q3 		$3 Buy
+1
New +$5 ﹤0.01% 1567

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Danske Bank's SNOA Position: Q2 2026 in Review

Danske Bank held its Sonoma Pharmaceuticals (SNOA) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Danske Bank first reported a position in SNOA in Q3 2024 and has held it in 8 quarters since. The position peaked at $4 in Q4 2025. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • Danske Bank held 1 share of Sonoma Pharmaceuticals worth $1 as of Q2 2026.
  • Danske Bank left its Sonoma Pharmaceuticals share count unchanged in Q2 2026.
  • Sonoma Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1148 holding.
  • Danske Bank first reported a position in Sonoma Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Danske Bank's Sonoma Pharmaceuticals position peaked at $4 in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.